REFERENCES
1. Lascelles BDX, Capner CA, Waterman-Pearson AE. Current British veterinary attitudes to perioperative analgesia for cats and
small mammals. Vet Rec 1999;145:601-604.
2. De Leo JA, Tawfik VL, LaCroix-Fralish ML. The tetrapartite synapse: path to CNS sensitization and chronic pain. Pain 2006;122(1-2):17-21.
3. Watkins LR, Milligan ED, Maier SF. Spinal cord glia: new players in pain. Pain 2001;93(3):201-205.
4. Taylor PM, Robertson SA, Dixon MJ, et al. Morphine, pethidine and buprenorphine disposition in the cat. J Vet Pharmacol Ther 2001;24(6):391-398.
5. Niedfeldt RL, Robertson SA. Postanesthetic hyperthermia in cats: a retrospective comparison between hydromorphone and buprenorphine.
Vet Anaesth Analg 2006;33(6):381-389.
6. Erichsen HK, Hao JX, Xu XJ, et al. Comparative actions of the opioid analgesics morphine, methadone and codeine in rat models
of peripheral and central neuropathic pain. Pain 2005;116(3):347-358.
7. Monteiro ER, Figueroa CD, Choma JC, et al. Effects of methadone, alone or in combination with acepromazine or xylazyine, on
sedation and physiologic values in dogs. Vet Anaesth Analg 2008;35(6):519-527.
8. Steagall PV, Carnicelli P, Taylor PM, et al. Effects of subcutaneous methadone, morphine, buprenorphine or saline on thermal
and pressure thresholds in cats. J Vet Pharmacol Ther 2006;29(6):531-537.
9. Krotscheck U, Boothe DM, Little AA. Pharmacokinetics of buprenorphine following intravenous administration in dogs. Am J Vet Res 2008;69(6):722-727.
10. Robertson SA, Taylor PM, Sear JW. Systemic uptake of buprenorphine by cats after oral mucosal administration. Vet Rec 2003;152(22):675-678.
11. Abbo LA, Ko JC, Maxwell LK, et al. Pharmacokinetics of buprenorphine following intravenous and oral transmucosal administration
in dogs. Vet Ther 2008;9(2):83-93.
12. Sawyer DC, Rech RH, Durham RA, et al. Dose response to butorphanol administered subcutaneously to increase visceral nociceptive
threshold in dogs. Am J Vet Res 1991;52(11):1826-1830.
13. Grimm KA, Tranquilli WJ, Thurmon JC, et al. Duration of nonresponse to noxious stimulation after intramuscular administration
of butorphanol, medetomidine, or a butorphanol-medetomidine combination during isoflurane administration in dogs. Am J Vet Res 2000;61(1):42-47.
14. Hay JL, La Vincente SF, Somogyi AA, et al. Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in
healthy subjects. Eur J Pain 2011;15(3):293-298.
15. Tzschentke TM, Christoph T, Kogel B, et al. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol
HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323(1):265-276.
16. Buprenorphine SR. Fort Collins, Colo: ZooPharm. Available at http://www.zoopharm.net/drugs/pdf/BuprenorphineSR.pdf.
17. Smith LJ, KuKanich B, Hogan BK, et al. Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered
to healthy dogs. J Vet Pharmacol Ther 2008;31(5):415-422.
18. Krugner-Higby L, Smith L, Schmidt B, et al. Experimental pharmacodynamics and analgesic efficacy of liposome-encapsulated
hydromorphone in dogs. J Am Anim Hosp Assoc 2011;47(3):185-195.
19. Carr, DB. Opioid side effects. In: IASP Pain Clinical Updates, April 2007 XV:2.
20. Gervitz C. Update on the management of opioid-induced constipation. Topics Pain Management 2007;23(3):1-5.
21. DeLeo JA, Sorkin LS, Watkins LR. Immune and glial regulation of pain. Seattle Wash: IASP Press, 2007.
22. Tremblay J, Hamet P. Genetics of pain, opioids, and opioid responsiveness. Metabolism 2010;59(Suppl 1):S5-S8.
|
Featuring Information from:
